Navitoclax is a potent inhibitor of both Bcl-2 and Bcl-XL activity [31] and has previously been shown to be an effective partner for cytotoxic agents including cytarabine in T-ALL cells [32] and solid tumor cell lines [33]. Here, BCL2 is linked to acute lymphoblastic leukemia.